论文部分内容阅读
目的研究巨噬细胞在肝癌组织中的分布,探讨其与临床病理因素及预后的关系。方法采用免疫组化二步法染色和细胞计数分析297例手术切除原发性肝癌患者石蜡标本切片中CD+68巨噬细胞的分布,分析CD+68巨噬细胞数目与临床病理因素关系,探讨其对预后的影响。结果 CD+68巨噬细胞低分布组术后1、2、3年无瘤生存率分别为66.0%、51.9%和45.9%,而高分布组1、2、3年无瘤生存率分别为58.6%、35.8%和29.0%。低分布组患者2年和3年无瘤生存率均好于高分布组,差异有统计学意义(2年对比P=0.0054,3年对比P=0.0026)。CD+68巨噬细胞低分布组1、2、3年总生存率分别为80.0%、65.2%和53.3%,而高分布组1、2、3年总生存率分别为74.7%、46.9%和37.0%。低分布组患者2年和3年总生存率好于高分布组,差异有统计学意义(2年对比P=0.0016,3年对比P=0.0049)。结论肝细胞癌组织中CD+68巨噬细胞与无瘤生存率和总生存率呈负相关,CD+68巨噬细胞越少,预后越好。
Objective To study the distribution of macrophages in hepatocellular carcinoma (HCC) and to explore its relationship with clinicopathological parameters and prognosis. Methods The distribution of CD + 68 macrophages in paraffin embedded sections of 297 patients with primary liver cancer underwent immunohistochemical two-step staining and cell counting. The relationship between the number of CD + 68 macrophages and clinicopathological factors was analyzed Its impact on prognosis. Results The 1-year, 2-year and 3-year survival rates of CD + 68 macrophages were 66.0%, 51.9% and 45.9% respectively, while the high-distribution group had no disease-free survival rates of 1, 2 and 3 years %, 35.8% and 29.0%. The 2-year and 3-year disease-free survival rates of patients with low distribution were significantly higher than those with high distribution (P = 0.0000 for 2 years and P = 0.0026 for 3 years). The overall 1, 2, 3-year overall survival rates of CD + 68 macrophages were 80.0%, 65.2% and 53.3%, respectively, while the 1-, 2- and 3-year overall survival rates were 74.7% and 46.9% 37.0%. The overall 2-year and 3-year overall survival rates of patients with low distribution were better than those with high distribution (P = 0.0000 for 2 years, P = 0.0049 for 3 years). Conclusion CD + 68 macrophages in hepatocellular carcinoma have a negative correlation with tumor-free survival and overall survival. The less CD + 68 macrophages, the better the prognosis.